The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Proteasome inhibitors in multiple myeloma: 10 years later
Open accessAbstract
Proteasome inhibition has emerged as an important therapeutic strategy in multiple myeloma (MM). Since the publication of the first phase 1 trials of bortezomib 10 years ago, this first-in-class proteasome inhibitor (PI) has contributed substantially to the observed improvement in survival in MM patients over the past decade. Although first approved as a single agent in the relapsed setting, bortezomib is now predominantly used in combination regimens. Furthermore, the standard twice-weekly schedule may be replaced by weekly infusion, especially when bortezomib is used as part of combination regimens in frontline therapy. Indeed, bortezomib is an established component of induction therapy for patients eligible or ineligible for autologous stem cell transplantation. Bortezomib has also been incorporated into conditioning regimens before autologous stem cell transplantation, as well as into post-ASCT consolidation therapy, and in the maintenance setting. In addition, a new route of bortezomib administration, subcutaneous infusion, has recently been approved. Recently, several new agents have been introduced into the clinic, including carfilzomib, marizomib, and MLN9708, and trials investigating these “second-generation” PIs in patients with relapsed/refractory MMs have demonstrated positive results. This review provides an overview of the role of PIs in the treatment of MM, focusing on developments over the past decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Self-citationOrlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Self-citationMateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Self-citationPalumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Self-citationEfficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381
Self-citation
Cited by
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Small-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 283
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Bortezomib for the treatment of multiple myeloma
Scott, K., Hayden, P. J., Will, A., Wheatley, K., & Coyne, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010816.pub2 · Cited by 158
Metadata
- Authors
- Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-08-02
- Volume
- 120
- Issue
- 5
- Pages
- 947-959
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2009426416
- Cited by
- 490
- References
- 7
- FWCI
- 32.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteasome inhibitors in multiple myeloma: 10 years later. https://app.cochat.ai/papers/10.1182/blood-2012-04-403733
- The paper
- Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012). Proteasome inhibitors in multiple myeloma: 10 years later. Blood. https://doi.org/10.1182/blood-2012-04-403733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
